A retrospective analysis of major cardiovascular adverse events (MACE) among adult new users of icosapent ethyl (IPE) has shown a reduction in events compared with new users of mixed omega-3 polysaturated fatty acid (OM-3) formulations.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
